Higher co-payments increase chance of early discontinuation of breast cancer therapy
A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer.
Dawn L. Hershman, MD, associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, will be presenting detailed study results at The 33rd CTRC-AACR San Antonio Breast Cancer Symposium, a comprehensive scientific meeting ...
